Opportunities in the Global Refractory Follicular Lymphoma Diagnostics Market include the growing need for MRD monitoring and ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor ...

At the recent American Society of Hematology (ASH) annual meeting, data from a phase I trial of AZD0486-- a novel CD19xCD3 bispecific T-cell engager -- showed high response rates and encouraging ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and longer-term data are needed to definitively determine its effectiveness.

The FDA has granted accelerated approval for a subcutaneous (SC) formulation of mosunetuzumab (Lunsumio VELO, Roche) for the treatment of certain adults with relapsed or refractory follicular lymphoma ...

Gazyva is a prescription injection medicine used for people with certain cancers, such as chronic lymphocytic leukemia (CLL) and certain types of follicular lymphoma. It is a type of medicine known as ...

Thanks to a clinical trial for follicular lymphoma at MSK, Michael is able to spend time with family, including his granddaughter, Natalia. Retired New York City police officer Michael T. had grown ...

(a) The smear is composed of blood only (smear, Diff-Quik stain). (b) The smear shows foamy macrophages and degenerated cyst fluid, with no follicular cells (smear, Diff-Quik stain). (c) Scant ...